BRL-50481

ATC code

• None

CAS Number

• 433695-36-4 ^Y

PubChem CID

• 2921148

IUPHAR/BPS

• 5154

BRL-50481

Clinical data
ATC code	None
Identifiers
IUPAC name N,N,2-Trimethyl-5-nitrobenzenesulfonamide
CAS Number	433695-36-4 Y
PubChem CID	2921148
IUPHAR/BPS	5154
ChemSpider	2194720 N
UNII	03G869PR3P
ChEBI	CHEBI:93472
ChEMBL	ChEMBL484928 N
CompTox Dashboard (EPA)	DTXSID30195832
Chemical and physical data
Formula	C9H12N2O4S
Molar mass	244.27 g·mol−1
3D model (JSmol)	Interactive image
SMILES Cc1ccc(N(=O)=O)cc1S(=O)(=O)N(C)C
InChI InChI=1S/C9H12N2O4S/c1-7-4-5-8(11(12)13)6-9(7)16(14,15)10(2)3/h4-6H,1-3H3 N Key:IFIUFCJFLGCQPH-UHFFFAOYSA-N N
NY (what is this?)  (verify)

BRL-50481 is a drug developed by GlaxoSmithKline which is the first compound that acts as a phosphodiesterase inhibitor selective for the PDE7 family.^[1] PDE7 activity is encoded by two genes, PDE7A and PDE7B. BRL-50481 actually shows about an 80-fold preference for the PDE7A subtype, for which it was developed, over PDE7B.^[2] BRL-50481 has been shown to increase mineralisation activity in osteoblasts, suggesting a potential role for PDE7 inhibitors in the treatment of osteoporosis.^[3]